LLY

712.25

-4.67%↓

JNJ

152.87

-0.45%↓

ABBV

181.75

-1.09%↓

NVO

66.83

-2.81%↓

UNH

297.81

-2.36%↓

LLY

712.25

-4.67%↓

JNJ

152.87

-0.45%↓

ABBV

181.75

-1.09%↓

NVO

66.83

-2.81%↓

UNH

297.81

-2.36%↓

LLY

712.25

-4.67%↓

JNJ

152.87

-0.45%↓

ABBV

181.75

-1.09%↓

NVO

66.83

-2.81%↓

UNH

297.81

-2.36%↓

LLY

712.25

-4.67%↓

JNJ

152.87

-0.45%↓

ABBV

181.75

-1.09%↓

NVO

66.83

-2.81%↓

UNH

297.81

-2.36%↓

LLY

712.25

-4.67%↓

JNJ

152.87

-0.45%↓

ABBV

181.75

-1.09%↓

NVO

66.83

-2.81%↓

UNH

297.81

-2.36%↓

Search

Cellectar Biosciences Inc

Gesloten

0.24 -7.69

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

0.23

Max

0.26

Belangrijke statistieken

By Trading Economics

Werknemers

11

Marktinformatie

By TradingEconomics

Marktkapitalisatie

280K

12M

Vorige openingsprijs

7.93

Vorige sluitingsprijs

0.24

Cellectar Biosciences Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

11 dec 2024, 18:44 UTC

Belangrijke Marktbewegers

Cellectar Biosciences Plunges on Pursuit of Strategic Options for Cancer Drug Candidate, 60% Workforce Cut

Peer Vergelijking

Prijswijziging

Cellectar Biosciences Inc Prognose

Beoordelingsconsensus

By TipRanks

Neutraal

2 ratings

0

Buy

2

Hold

0

Sell

Financieel

$

Over Cellectar Biosciences Inc

Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia cohort, r/r multiple myeloma (MM) cohort, and r/r non-Hodgkin's lymphoma cohort; Phase 1 clinical study for r/r pediatric patients with select solid tumors, lymphomas, and malignant brain tumors; and Phase 1 clinical study for r/r head and neck cancer. The company also develops CLR 1900, a PDC chemotherapeutic program that is in the preclinical development stage to treat solid tumors. It has collaborative with Orano Med to develop CLR 12120 Series; and LegoChemBio. The company was founded in 2002 and is headquartered in Florham Park, New Jersey.